Digital health market intelligence
Evidence for decisions shaping digital health
Galen Growth actively tracks digital health investment, innovation, partnerships, and evidence—combining a decade of market history with current research and analysis.
Explore our intelligence
Four ways to use the research
Research Library
Published reports on funding, ecosystems, innovation, evidence, and market development.
02Insights
Editorial analysis of the events, companies, and strategic shifts shaping digital health.
03HealthTech 250
The annual evidence-led selection of promising early-stage digital health ventures.
04Guides & Tools
Static practical resources for market evaluation, diligence, and healthcare innovation.
Latest insight
Recent analysis
Build, Buy or Partner: How to Spend a 2027 Digital Health Budget
The AI label now carries a 16% funding discount and acquired ventures average 10.7 years old. How to choose between building, buying and partnering in 2027.
Read the analysisResearch library
Recent reports
Health Management Solutions: Health Revolution Congress 2026
Presented by Galen Growth at Health Revolution Congress 2026 in Barcelona, this presentation explores how Health Management Solutions are becoming the operating layer of modern healthcare as AI adoption, investment and enterprise-scale deployment accelerate.
Exits Are Back. Easy Exits Aren't.
M&A now accounts for 95% of digital health exits as the IPO window stays shut to all but the most evidence-led ventures. Galen Growth's Digital Health Exits 2026 report — powered by HealthTech Alpha — analyses 282 exits from 2025 to June 2026 and the Roche/PathAI deal that turns vendor neutrality into a board-level governance question.
Global Digital Health Funding and Key Trends 2025: Re-priced, Re-proved, Re-focused
In 2025, capital snapped back only for real performers—ventures proving adoption, unit economics, and execution. Health systems tightened the rules, demanding workflow fit and ROI. Evidence, interoperability, and distribution now separate contenders from pretenders as the market reopens, raising the stakes for anyone who can’t deliver measurable value.